Therapeutic potential of folate uptake inhibition in Plasmodium falciparum

Trends in Parasitology

Volumn 20, Issue 3, 2004, Pages 109-112

  Nzila, Alexis M ^a   Kokwaro, Gilbert ^a   Winstanley, Peter A ^b   Marsh, Kevin ^a   Ward, Steve A ^c  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLORCYCLOGUANIL; DAPSONE; DIHYDROFOLATE REDUCTASE INHIBITOR; FANSIDAR; FOLIC ACID ANTAGONIST; METHOTREXATE; PENICILLIN G; PROBENECID; PYRIMETHAMINE; SULFADOXINE; URICOSURIC AGENT;

ANTIBIOTIC RESISTANCE; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; GOUT; HUMAN; IC 50; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PLASMODIUM FALCIPARUM; REVIEW;

PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 1342328135     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2003.12.005     Document Type: Short Survey

References (31)

1. Mutabingwa T., et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet. 358:2001;1218-1223.
2. Nzila A.M., et al. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob. Agents Chemother. 44:2000;991-996.
3. Staedke S.G., et al. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet. 358:2001;368-374.
4. Terlouw D.J., et al. Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya. J. Infect. Dis. 187:2003;467-476.
5. Sibley C.H., et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 17:2001;582-588.
6. Kinyanjui S.M., et al. The antimalarial triazine WR99210 and the prodrug PS-15: folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug. Am. J. Trop. Med. Hyg. 60:1999;943-947.
7. van Hensbroek M.B., et al. Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 89:1995;672-676.
8. Watkins W.M., et al. Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. Mol. Biochem. Parasitol. 14:1985;55-61.
9. Wang P., et al. A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance. Parasitology. 115:1997;223-230.
10. Wang P., et al. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy. Mol. Microbiol. 32:1999;1254-1262.
11. Sirotnak F.M., et al. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin. Cancer Res. 6:2000;3705-3712.
12. Bertino J.R. Karnofsky memorial lecture. Ode to methotrexate. J. Clin. Oncol. 11:1993;5-14.
13. Matherly L.H. Molecular and cellular biology of the human reduced folate carrier. Prog. Nucleic Acid Res. Mol. Biol. 67:2001;131-162.
14. Sierra E.E., Goldman I.D. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin. Oncol. 26:1999;11-23.
15. Sirotnak F.M., Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu. Rev. Nutr. 19:1999;91-122.
16. Antony A.C. Folate receptors. Annu. Rev. Nutr. 16:1996;501-521.
17. Banerjee D., et al. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim. Biophys. Acta. 1587:2002;164-173.
18. Guo W., et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin. Cancer Res. 5:1999;621-627.
19. Gorlick R., et al. Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation. Adv. Exp. Med. Biol. 457:1999;543-550.
20. Hooijberg J.H., et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59:1999;2532-2535.
21. Borst P., et al. The multidrug resistance protein family. Biochim. Biophys. Acta. 1461:1999;347-357.
22. Borst P., et al. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:2000;1295-1302.
23. Borst P., et al. ABC transporters in lipid transport. Biochim. Biophys. Acta. 1486:2000;128-144.
24. Nzila A., et al. Chemosensitization of Plasmodium falciparum by probenecid in vitro. Antimicrob. Agents Chemother. 47:2003;2108-2112.
25. Watkins W.M., et al. The efficacy of antifolate antimalarial combination in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol. Today. 13:1997;459-464.
26. Sekine T., et al. The multispecific organic anion transporter (OAT) family. Pflugers Arch. 440:2000;337-350.
27. Takeda M., et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther. 302:2002;666-671.
28. Sierra E.E., Goldman I.D. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin. Oncol. 26:1999;11-23.
29. Fidock D.A., Wellems T.E. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc. Natl. Acad. Sci. U. S. A. 94:1997;10931-10936.
30. Walter R., et al. Pyrimethamine-resistant Plasmodium falciparum lack cross-resistance to methotrexate and 2,4-diamino-5-(substituted benzyl) pyrimidines. Parasitol. Res. 77:1991;346-350.
31. Cunningham R.F., et al. Clinical pharmacokinetics of probenecid. Clin. Pharmacokinet. 6:1981;135-151.